STOCK TITAN

Orthofix Medical Inc - OFIX STOCK NEWS

Welcome to our dedicated news page for Orthofix Medical (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orthofix Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orthofix Medical's position in the market.

Rhea-AI Summary
Orthofix Medical Inc. (NASDAQ:OFIX) announced the appointment of Lucas Vitale as Chief People and Business Operations Officer. Vitale brings extensive experience in spine and orthopedics, having served in key roles at companies like NuVasive, Inc. His role will focus on integration and business transformation strategies to support future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
none
-
Rhea-AI Summary
Orthofix Medical Inc. (OFIX) reported strong financial results for Q4 2023 with net sales of $200.4 million, a 64% increase on a reported basis. The company achieved 15% growth in Bone Growth Therapies sales, marking four consecutive quarters of double-digit growth. Despite a net loss of $22 million, the Non-GAAP Adjusted EBITDA was $20 million, representing 96% growth over the previous year. Full-year net sales reached $746.6 million, a 62% increase, with Non-GAAP adjusted EBITDA of $46.3 million, a 69% growth over the prior year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.69%
Tags
earnings
-
Rhea-AI Summary
Orthofix Medical Inc. appoints Jason Shallenberger as President of Bone Growth Therapies and realigns its Spine business unit. Shallenberger, a seasoned sales leader, has a successful track record of driving double-digit growth. The move aims to enhance the company's focus on Biologics and Enabling Technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
Rhea-AI Summary
Orthofix Medical Inc. (OFIX) will report its Q4 and full year 2023 financial results on March 5, 2024. A conference call and webcast will follow to discuss the outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
earnings
-
Rhea-AI Summary
Orthofix Medical Inc. (NASDAQ:OFIX) has announced an agreement with MRIguidance to distribute its BoneMRI™ imaging software in the U.S. The company completed the world's first eight cases using BoneMRI software with 7D's FLASH™ Navigation System, providing completely radiation-free preoperative imaging and spinal navigation. The 7D FLASH Navigation System uses visible light to create a three-dimensional image for surgical navigation, enabling faster and more efficient spinal procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
partnership
-
Rhea-AI Summary
Orthofix Medical Inc. (OFIX) announced the appointment of Julie Andrews as the new Chief Financial Officer. Ms. Andrews brings over 25 years of leadership experience in the medical device sector, previously serving as CFO for Smart Wires Technology and Senior Vice President, Global Finance for Wright Medical Group. Orthofix CEO, Massimo Calafiore, expressed confidence in Ms. Andrews' ability to drive sustainable shareholder value. Ms. Andrews also expressed her excitement to join Orthofix and work towards improving the company's performance and accelerating its business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
Rhea-AI Summary
Orthofix Medical Inc. (OFIX) reports a 64% increase in net sales to $200.3 million for Q4 2023, with Bone Growth Therapies growing 15% and U.S. Spinal Implants, Biologics, and Enabling Technologies growing 4%. Full-year net sales for 2023 were $746.5 million, a 62% increase over 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.78%
Tags
none
-
Rhea-AI Summary
Orthofix Medical Inc. (NASDAQ: OFIX) announced the appointment of Massimo Calafiore as President and CEO, effective immediately, and Julie Andrews as Chief Financial Officer, effective January 15, 2024. Calafiore brings extensive experience, and Andrews has a strong financial background. Catherine Burzik, Chair of the Board, expressed confidence in the new executives' vision and leadership. Calafiore stated his commitment to the company's mission and welcomed Andrews to the team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
management
-
Rhea-AI Summary
Orthofix Medical Inc. (NASDAQ: OFIX) announced the appointment of Massimo Calafiore as President and CEO, effective immediately, and Julie Andrews as Chief Financial Officer, effective January 15, 2024. Calafiore brings extensive experience, and Andrews has a strong financial background. Catherine Burzik, Chair of the Board, expressed confidence in the new executives' vision and leadership. Calafiore stated his commitment to the company's mission and welcomed Andrews to the team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.89%
Tags
management
Rhea-AI Summary
Orthofix Medical Inc. (NASDAQ:OFIX) announced new data from a study on Pulsed Electromagnetic Field (PEMF) stimulation as a therapy for spinal fusion procedures. The study showed a high rate of successful fusion and significant improvements in pain, function, and quality of life for patients at risk for pseudarthrosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
none
Orthofix Medical Inc

Nasdaq:OFIX

OFIX Rankings

OFIX Stock Data

534.54M
26.23M
3.58%
97.52%
9.67%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Lewisville

About OFIX

orthofix international began in a small farmhouse in verona italy in 1980 when orthopedic researcher giovanni de bastiani recognized the bone’s natural repair capability, a concept he called “dynamization” and with that in mind, he created the first external fixation device. today, orthofix has grown to more than 900 employees with locations in the u.s., italy, germany, france, the uk, brazil, australia and puerto rico. our products help patients in 70 countries around the world. the company is comprised of four strategic business units; biostim, biologics, extremity fixation and spine fixation. our products are widely distributed via the company's sales representatives, distributors and subsidiaries. at orthofix we are committed to clinical research and driven by new product introductions. we are proud of our strong partnerships with organizations such as the texas scottish rite hospital for children in dallas and the musculoskeletal transplant foundation. we take pride in developing